

Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis from the 2020 ASH Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Updated analysis of the GRIFFIN trial evaluating the addition of daratumumab to lenalidomide, bortezomib and dexamethasone for patients with newly diagnosed multiple myeloma (MM) who were transplant-eligible demonstrated an improvement in which of the following outcomes with daratumumab?
 - a. Stringent complete response rate (sCR) only
 - b. Minimal residual disease (MRD) negativity rate only
 - c. Both sCR rate and MRD negativity rate
2. What is the target of the CAR (chimeric antigen receptor) T-cell therapy evaluated in the CARTITUDE-1 study for patients with MM?
 - a. CD19
 - b. B-cell maturation antigen (BCMA)
 - c. CD20
3. Which of the following strategies has been used successfully to manage the nausea associated with selinexor and dexamethasone for patients with relapsed/refractory MM?
 - a. Dose reduction only
 - b. Use of antiemetics only
 - c. Both dose reduction and antiemetics
4. Which of the following drug types best describes the mechanism of action of the novel agent iberdomide?
 - a. Anti-CD38 antibody
 - b. Bcl-2 inhibitor
 - c. BCMA-targeted agent
 - d. Cereblon E3 ligase modulator